Fluzone® High-Dose Influenza Vaccine.
Fluzone® High-Dose (IIV3-HD) is a trivalent, inactivated, split-virus influenza vaccine indicated for use in older adults (≥65 years of age). It contains 60 µg hemagglutinin of each influenza strain, which is four times the hemagglutinin content of standard-dose influenza vaccines, including Fluzone (IIV3-SD). IIV3-HD has been licensed for use in older adults in the US since December 2009 and in Canada since February 2016. Areas covered: In this review, we summarize postlicensure studies on the immunogenicity, safety, and effectiveness of IIV3-HD and estimates of its cost-effectiveness in older adults. We also discuss the potential application of IIV3-HD in adults 50-64 years of age and in individuals who may respond poorly to standard-dose influenza vaccines. Expert commentary: Multiple studies conducted since 2004 have consistently shown that, in older adults, IIV3-HD induces substantially greater antibody responses and better protection against influenza and influenza-associated hospitalization than IIV3-SD. Health economic analyses suggest that IIV3-HD can be a cost-effective alternative to standard-dose trivalent or quadrivalent inactivated influenza vaccines and can even be cost-saving compared to IIV3-SD in older adults. Further investigation of IIV3-HD vaccination as a way to improve immune responses and protection against influenza in immunocompromised individuals is warranted.
a Sanofi Pasteur Inc. , Swiftwater , PA , USA.
Corwin A
CA
Robertson
a Sanofi Pasteur Inc. , Swiftwater , PA , USA.
Carlos A
CA
DiazGranados
a Sanofi Pasteur Inc. , Swiftwater , PA , USA.|b Department of Health Policy , Vanderbilt University School of Medicine , Nashville , TN , USA.
Michael D
MD
Decker
a Sanofi Pasteur Inc. , Swiftwater , PA , USA.|c Leslie Dan Faculty of Pharmacy , University of Toronto , Toronto , Canada.
Ayman
A
Chit
a Sanofi Pasteur Inc. , Swiftwater , PA , USA.
Monica
M
Mercer
a Sanofi Pasteur Inc. , Swiftwater , PA , USA.|d Department of Pediatrics , University of Pittsburgh School of Medicine , Pittsburgh , PA , USA.
David P
DP
Greenberg
D000368:Aged; D000369:Aged, 80 and over; D000914:Antibodies, Viral / Q000097:blood; D002170:Canada; D003362:Cost-Benefit Analysis; D006760:Hospitalization; D006801:Humans; D007252:Influenza Vaccines / Q000008:administration & dosage / Q000009:adverse effects* / Q000191:economics / Q000276:immunology*; D007251:Influenza, Human / Q000517:prevention & control*; D008875:Middle Aged; D011358:Product Surveillance, Postmarketing; D014481:United States
D000914:Antibodies, Viral; C000618615:Fluzone High-Dose; D007252:Influenza Vaccines
Influenza; high-dose; immunocompromising conditions; immunosenescence; older adults; vaccine